Correct Answer: D. Liver
Insulin-like growth factor I (IGF-I) is predominantly synthesized and secreted by the liver, accounting for ~75% of circulating IGF-I. This is a critical distinction in endocrinology: while growth hormone (GH) is produced by the anterior pituitary somatotrophs, GH acts on the liver to stimulate IGF-I production via the somatomedin hypothesis. The liver is the primary endocrine source of circulating IGF-I, which then acts systemically on target tissues (bone, muscle, cartilage) to mediate growth effects. IGF-I also has autocrine and paracrine functions in non-hepatic tissues, but the circulating pool—which is what clinical assays measure—originates predominantly from hepatic synthesis. This distinction is crucial in clinical practice: in liver disease (cirrhosis, hepatitis), circulating IGF-I levels fall despite normal or elevated GH, reflecting impaired hepatic synthesis. Conversely, in acromegaly, both GH and IGF-I are elevated. The GH→IGF-I axis is fundamental to understanding growth disorders in Indian pediatric practice, where malnutrition and chronic liver disease commonly impair this pathway.
Why the other options are wrong
A. Pancreas — The pancreas produces insulin and glucagon for glucose homeostasis, not IGF-I. While pancreatic beta cells are endocrine, they have no role in IGF-I synthesis. This is a trap for students who conflate 'insulin' with 'insulin-like growth factor'—they are structurally similar but functionally and anatomically distinct. B. Adrenal glands — Adrenal glands produce cortisol, aldosterone, catecholamines, and androgens—not IGF-I. While adrenal hormones modulate growth indirectly (cortisol inhibits growth), the adrenal cortex and medulla have no direct role in IGF-I synthesis. This option exploits confusion about which endocrine glands regulate growth. C. Pituitary gland — The pituitary produces GH, which stimulates IGF-I production in the liver—but does not produce IGF-I itself. This is the classic NBE trap: students who know GH drives growth may incorrectly assume the pituitary also makes IGF-I. The somatomedin hypothesis clearly establishes the liver as the target organ for GH action.
High-Yield Facts
- Liver produces ~75% of circulating IGF-I; the remaining 25% comes from autocrine/paracrine synthesis in bone, muscle, and other tissues.
- GH→IGF-I axis: pituitary GH stimulates hepatic IGF-I synthesis; IGF-I then exerts negative feedback on GH secretion (somatomedin hypothesis).
- Liver disease impairs IGF-I: cirrhosis, hepatitis, and malnutrition reduce hepatic IGF-I synthesis despite normal/high GH—a key clinical discriminator.
- IGF-I has dual action: endocrine (circulating from liver) and autocrine/paracrine (local tissue production); clinical assays measure the hepatic endocrine pool.
- IGF-I mediates GH effects on growth: GH itself does not directly stimulate bone/muscle growth; IGF-I is the effector hormone for linear growth and protein synthesis.
Mnemonics
GH → Liver → IGF-I (The Somatomedin Axis) Growth Hormone (pituitary) → Liver → Insulin-like Growth Factor-I. Pituitary makes GH; liver makes IGF-I in response to GH. Use this when asked 'where is IGF-I made?' LIVER = Largest source of circulating IGF-I Liver produces IGF-I; Very important for growth; Endocrine source (circulating); Regulated by GH. Helps distinguish hepatic endocrine IGF-I from local tissue production.
NBE Trap
NBE pairs 'growth hormone' with 'pituitary' to lure students into selecting the pituitary as the source of IGF-I. The somatomedin hypothesis—that GH acts via IGF-I rather than directly—is the key discriminator that separates correct from incorrect answers.
Clinical Pearl
In Indian pediatric practice, children with protein-calorie malnutrition (PEM) have low circulating IGF-I despite normal GH levels—this reflects impaired hepatic synthesis, not GH deficiency. Similarly, children with chronic liver disease (viral hepatitis, cirrhosis) fail to grow despite adequate GH, because the liver cannot produce IGF-I. This dissociation is diagnostic and guides management toward nutritional rehabilitation rather than GH therapy.
_Reference: Guyton & Hall Textbook of Medical Physiology, Ch. 75 (Growth and Metabolism); Harrison's Principles of Internal Medicine, Ch. 395 (Disorders of Growth and Development)_